BioCentury | Mar 5, 2021
Product Development

Lilly’s tirzepatide more potent than Novo’s semaglutide, but higher discontinuation: Data Byte

...indicate Lilly’s tirzepatide bests Novo’s semaglutide on multiple efficacy metrics for Type II diabetes, but saw...
BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

...of public biotechs valued at more than $1 billion since the beginning of 2020, Pandion saw...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...with exits driving fund size increases that saw...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...small part of what the company is working on.Of syndicates and SoftbankThe series C round saw...
BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

...of clinical CAR T data that also saw...
...mode of antigen escape they identified: both saw...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

...round it raised in March 2020. CAM Capital and Polaris Partners led Primmune’s A round, which saw...
BioCentury | Feb 18, 2021
Finance

Eyeing functional cure, Excision raises $60M to advance CRISPR-based HIV program into Phase I/II

...HIV infection is expected to start this year.GreatPoint Ventures led Wednesday’s funding round, which also saw...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

...capital from institutional LPs to invest in biotech. The once star of British biotech fundraising saw...
BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...Thursday, Merck reported $48 billion in total 2020 sales, including $14.4 billion from Keytruda, which saw...
BioCentury | Feb 2, 2021
Deals

Gritstone seeks value in infectious diseases through Gilead deal, but isn’t leaving neoantigens behind

...proof of concept for the platform, Gilead saw...
Items per page:
1 - 10 of 1610
BioCentury | Mar 5, 2021
Product Development

Lilly’s tirzepatide more potent than Novo’s semaglutide, but higher discontinuation: Data Byte

...indicate Lilly’s tirzepatide bests Novo’s semaglutide on multiple efficacy metrics for Type II diabetes, but saw...
BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

...of public biotechs valued at more than $1 billion since the beginning of 2020, Pandion saw...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...with exits driving fund size increases that saw...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...small part of what the company is working on.Of syndicates and SoftbankThe series C round saw...
BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

...of clinical CAR T data that also saw...
...mode of antigen escape they identified: both saw...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

...round it raised in March 2020. CAM Capital and Polaris Partners led Primmune’s A round, which saw...
BioCentury | Feb 18, 2021
Finance

Eyeing functional cure, Excision raises $60M to advance CRISPR-based HIV program into Phase I/II

...HIV infection is expected to start this year.GreatPoint Ventures led Wednesday’s funding round, which also saw...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

...capital from institutional LPs to invest in biotech. The once star of British biotech fundraising saw...
BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...Thursday, Merck reported $48 billion in total 2020 sales, including $14.4 billion from Keytruda, which saw...
BioCentury | Feb 2, 2021
Deals

Gritstone seeks value in infectious diseases through Gilead deal, but isn’t leaving neoantigens behind

...proof of concept for the platform, Gilead saw...
Items per page:
1 - 10 of 1610